Incyte (INCY) Stock Forecast & Price Target

Compare

1,914 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

INCY Analyst Ratings

Moderate Buy

8 Buy

8 Hold

1 Sell

Based on 17 analysts giving stock ratings to

Incyte

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

INCY Stock 12 Month Forecast

Average Price Target

$110.53

▲(19.44% Upside)

Based on 17 Wall Street analysts offering 12 month price targets for Incyte in the last 3 months. The average price target is $110.53 with a high forecast of $135.00 and a low forecast of $75.00. The average price target represents a 19.44% change from the last price of $92.54.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"59":"$59","136":"$136","78.25":"$78.3","97.5":"$97.5","116.75":"$116.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":135,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$135.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":110.53,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$110.53</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$75.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[59,78.25,97.5,116.75,136],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2025","6":"Sep<br/>2025","9":"Dec<br/>2025","12":"Mar<br/>2026","25":"Mar<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,100.04,102.72923076923078,105.41846153846154,108.10769230769232,110.79692307692308,113.48615384615385,116.17538461538462,118.86461538461539,121.55384615384615,124.24307692307693,126.93230769230769,129.62153846153845,132.31076923076924,{"y":135,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,100.04,100.84692307692308,101.65384615384616,102.46076923076923,103.26769230769231,104.07461538461538,104.88153846153847,105.68846153846154,106.49538461538462,107.30230769230769,108.10923076923078,108.91615384615385,109.72307692307692,{"y":110.53,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,100.04,98.11384615384615,96.18769230769232,94.26153846153846,92.33538461538463,90.40923076923077,88.48307692307692,86.55692307692308,84.63076923076923,82.70461538461538,80.77846153846154,78.85230769230769,76.92615384615385,{"y":75,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":73.5,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.91,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.03,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 29, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.31,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":68.73,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":75.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.98,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93.48,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.04,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.77,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.67,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100.04,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 36,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$135.00

Average Price Target$110.53

Lowest Price Target$75.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Stephen Willey

Stifel Nicolaus

$120

Buy

29.67%

Upside

Reiterated

03/09/26

Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Incyte (INCY)

Mitchell Kapoor

H.C. Wainwright

$135

Buy

45.88%

Upside

Reiterated

03/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Incyte (NASDAQ: INCY) and Oncology Institute (NASDAQ: TOI)

Michael Schmidt

Guggenheim

$130

Buy

40.48%

Upside

Reiterated

03/06/26

Guggenheim Remains a Buy on Incyte (INCY)

Ashwani Verma

UBS

$104

Hold

12.38%

Upside

Reiterated

03/06/26

Balancing Post‑Jakafi Opportunities and Execution Risks: Rationale Behind a Neutral Stance on Incyte

Matt Phipps

William Blair

―

Hold

―

Reiterated

03/05/26

Analysts Offer Insights on Healthcare Companies: Immatics (NASDAQ: IMTX) and Incyte (NASDAQ: INCY)

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

$73→$110

Hold

18.87%

Upside

Reiterated

03/05/26

Evercore ISI Remains a Hold on Incyte (INCY)

Etzer Darout

Barclays

$117

Buy

26.43%

Upside

Reiterated

03/03/26

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Incyte (NASDAQ: INCY) and Radnet (NASDAQ: RDNT)

Marc Frahm

TD Cowen

$123

Buy

32.92%

Upside

Reiterated

03/02/26

Analysts Are Bullish on These Healthcare Stocks: Rocket Pharmaceuticals (RCKT), Option Care Health (OPCH)

Derek Archila

Wells Fargo

$107→$101

Hold

9.14%

Upside

Reiterated

02/11/26

Wells Fargo Remains a Hold on Incyte (INCY)

Srikripa Devarakonda

Truist Financial

―

Hold

―

Reiterated

02/11/26

Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY), Zimmer Biomet Holdings (NYSE: ZBH) and Theravance Biopharma (NASDAQ: TBPH)

Evan Seigerman

BMO Capital

$75

Sell

-18.95%

Downside

Reiterated

02/11/26

Incyte (INCY) Receives a Sell from BMO Capital

Salveen Richter

Goldman Sachs

$90→$98

Hold

5.90%

Upside

Reiterated

02/11/26

Analysts Offer Insights on Healthcare Companies: Neuronetics (NASDAQ: STIM), Incyte (NASDAQ: INCY) and Zimmer Biomet Holdings (NYSE: ZBH)

Clara Dong

Jefferies

$120

Buy

29.67%

Upside

Reiterated

02/11/26

Jefferies Keeps Their Buy Rating on Incyte (INCY)

Judah Frommer

Morgan Stanley

$94→$102

Hold

10.22%

Upside

Reiterated

02/11/26

Incyte (INCY) Receives a Hold from Morgan Stanley

Brian Abrahams

RBC Capital

$95→$92

Hold

-0.58%

Downside

Reiterated

02/10/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (NASDAQ: INCY), Edwards Lifesciences (NYSE: EW) and Royalty Pharma (NASDAQ: RPRX)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Stephen Willey

Stifel Nicolaus

$120

Buy

29.67%

Upside

Reiterated

03/09/26

Analysts' Top Healthcare Picks: Revolution Medicines (RVMD), Incyte (INCY)

Mitchell Kapoor

H.C. Wainwright

$135

Buy

45.88%

Upside

Reiterated

03/09/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Roche Holding AG (Other OTC: RHHVF), Incyte (NASDAQ: INCY) and Oncology Institute (NASDAQ: TOI)

Michael Schmidt

Guggenheim

$130

Buy

40.48%

Upside

Reiterated

03/06/26

Guggenheim Remains a Buy on Incyte (INCY)

Ashwani Verma

UBS

$104

Hold

12.38%

Upside

Reiterated

03/06/26

Balancing Post‑Jakafi Opportunities and Execution Risks: Rationale Behind a Neutral Stance on Incyte

Matt Phipps

William Blair

―

Hold

―

Reiterated

03/05/26

Analysts Offer Insights on Healthcare Companies: Immatics (NASDAQ: IMTX) and Incyte (NASDAQ: INCY)

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

$73→$110

Hold

18.87%

Upside

Reiterated

03/05/26

Evercore ISI Remains a Hold on Incyte (INCY)

Etzer Darout

Barclays

$117

Buy

26.43%

Upside

Reiterated

03/03/26

Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (NASDAQ: ASND), Incyte (NASDAQ: INCY) and Radnet (NASDAQ: RDNT)

Marc Frahm

TD Cowen

$123

Buy

32.92%

Upside

Reiterated

03/02/26

Analysts Are Bullish on These Healthcare Stocks: Rocket Pharmaceuticals (RCKT), Option Care Health (OPCH)

Derek Archila

Wells Fargo

$107→$101

Hold

9.14%

Upside

Reiterated

02/11/26

Wells Fargo Remains a Hold on Incyte (INCY)

Srikripa Devarakonda

Truist Financial

―

Hold

―

Reiterated

02/11/26

Analysts Conflicted on These Healthcare Names: Incyte (NASDAQ: INCY), Zimmer Biomet Holdings (NYSE: ZBH) and Theravance Biopharma (NASDAQ: TBPH)

Evan Seigerman

BMO Capital

$75

Sell

-18.95%

Downside

Reiterated

02/11/26

Incyte (INCY) Receives a Sell from BMO Capital

Salveen Richter

Goldman Sachs

$90→$98

Hold

5.90%

Upside

Reiterated

02/11/26

Analysts Offer Insights on Healthcare Companies: Neuronetics (NASDAQ: STIM), Incyte (NASDAQ: INCY) and Zimmer Biomet Holdings (NYSE: ZBH)

Clara Dong

Jefferies

$120

Buy

29.67%

Upside

Reiterated

02/11/26

Jefferies Keeps Their Buy Rating on Incyte (INCY)

Judah Frommer

Morgan Stanley

$94→$102

Hold

10.22%

Upside

Reiterated

02/11/26

Incyte (INCY) Receives a Hold from Morgan Stanley

Brian Abrahams

RBC Capital

$95→$92

Hold

-0.58%

Downside

Reiterated

02/10/26

Analysts Have Conflicting Sentiments on These Healthcare Companies: Incyte (NASDAQ: INCY), Edwards Lifesciences (NYSE: EW) and Royalty Pharma (NASDAQ: RPRX)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Incyte

3 Months

xxx

Success Rate

15/22 ratings generated profit

Average Return

+6.10%

reiterated a xxx

rating 10 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 68.18% of your transactions generating a profit, with an average return of +6.10% per trade.

1 Year

David LebowitzCiti

Success Rate

15/15 ratings generated profit

Average Return

+26.09%

reiterated a buy rating 8 months ago

Copying David Lebowitz's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +26.09% per trade.

2 Years

xxx

Success Rate

15/15 ratings generated profit

Average Return

+45.10%

reiterated a xxx

rating 8 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +45.10% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

INCY Analyst Recommendation Trends

Rating

Nov 25

Dec 25

Jan 26

Feb 26

Mar 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, INCY has received 36 Buy Ratings, 18 Hold Ratings, and 3 Sell Ratings. INCY average Analyst price target in the past 3 months is 110.53.

Each month's total comprises the sum of three months' worth of ratings.

INCY Financial Forecast

INCY Earnings Forecast

Next quarter’s earnings estimate for INCY is $1.42 with a range of $1.12 to $1.81. The previous quarter’s EPS was $1.80. INCY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year INCY has Performed in-line its overall industry.

INCY Sales Forecast

Next quarter’s sales forecast for INCY is $1.25B with a range of $1.17B to $1.33B. The previous quarter’s sales results were $1.51B. INCY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year INCY has Performed in-line its overall industry.

INCY Stock Forecast FAQ

What is INCY’s average 12-month price target, according to analysts?

Based on analyst ratings, Incyte Corp’s 12-month average price target is 110.53.

What is INCY’s upside potential, based on the analysts’ average price target?

Incyte Corp has 19.44% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is INCY a Buy, Sell or Hold?

Incyte Corp has a consensus rating of Moderate Buy which is based on 8 buy ratings, 8 hold ratings and 1 sell ratings.

What is Incyte Corp’s price target?

The average price target for Incyte Corp is 110.53. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $135.00 ,the lowest forecast is $75.00. The average price target represents 19.44% Increase from the current price of $92.54.

What do analysts say about Incyte Corp?

Incyte Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.

How can I buy shares of INCY?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Incyte (INCY) Stock Forecast & Price Target

INCY Analyst Ratings

INCY Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Incyte

INCY Analyst Recommendation Trends

INCY Financial Forecast

INCY Earnings Forecast

INCY Sales Forecast

INCY Stock Forecast FAQ

Detailed List of Analyst Forecasts